Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.41 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802703 | 0.91 | MAPK8 (0.42) | ACACBMAPK8MAPK9MERTKSYK | |
| SCHEMBL19665603 | 0.86 | MAPK8 (0.44) | ACACBCCNA2CDK2CCNA1MAPK8 | |
| SCHEMBL29802488 | 0.85 | PRKCQ (0.43) | ACACBCCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL19665681 | 0.80 | MAPK8 (0.47) | MAPK8MAPK9SYK | |
| SCHEMBL27564409 | 0.77 | SYK (0.45) | SYK | |
| SCHEMBL29802533 | 0.77 | PRKCQ (0.42) | ACACBCDK2MAPK8MAPK9MERTK | |
| SCHEMBL19665632 | 0.76 | MAPK8 (0.43) | ACACBCCNA2CDK2CCNA1MAPK8 | |
| SCHEMBL29802436 | 0.74 | STK17B (0.37) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL19665692 | 0.74 | EPHX1 (0.50) | CCNA2CDK2MERTKSYK | |
| SCHEMBL19665710 | 0.73 | MAPK8 (0.45) | MAPK8MAPK9MERTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | ACACB 4363/4885CCNE2 1848/4885CCNA2 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.